Biocius Buy Key to Agilent's Clinical Proteomics Plans

While Biocius' RapidFire technology has traditionally been used by pharma firms for drug-screening work, "one of the key opportunities" Agilent sees is applying the platform "to the clinical proteomics space," a company official said.